Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.

Current hematologic malignancy reports - 1 Dec 2013

Zeidan Amer M, Komrokji Rami S

Abstract excerpt

Myelodysplastic syndromes (MDS) include a diverse group of clonal hematopoietic disorders characterized by progressive cytopenias and propensity for leukemic progression. The biologic heterogeneity that underlies MDS translates clinically in wide variations of clinical outcomes. Several prognostic schemes were developed to predict the natural course of MDS, counsel patients, and allow evidence-based,...

Topics

Antineoplastic Agents
Cytogenetic Analysis
Disease Management
Genotype
Humans
Myelodysplastic Syndromes
Predictive Value of Tests
Prognosis
Risk Assessment
World Health Organization

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 23979829
DOI: 10.1007/s11899-013-0172-3
PMCID: PMC4133773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.PMID 23979829Read ↗

The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Current state of prognostication and risk stratification in myelodysplastic syndromes.Semantic proximity Read ↗

Novel Prognostic Models for Myelodysplastic Syndromes.Semantic proximity Read ↗

The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.Semantic proximity Read ↗

Updates in Risk Stratification in Myelodysplastic Syndromes.Semantic proximity Read ↗

Prognostic models in myelodysplastic syndromes.Semantic proximity Read ↗

When to use which molecular prognostic scoring system in the management of patients with MDS?Semantic proximity Read ↗

Clinical and genetic predictors of prognosis in myelodysplastic syndromesSemantic proximity Read ↗

Improving Prognostic Modeling in Myelodysplastic Syndromes.Semantic proximity Read ↗

Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.Semantic proximity Read ↗

MDS prognostic scoring systems – past, present, and future.Semantic proximity Read ↗

Myelodysplastic syndromes classification and risk stratification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.